[Skip to Content]
[Skip to Content Landing]
September 18, 1943


Author Affiliations


From the Division of Internal Medicine, University of Minnesota Hospitals and Medical School.

JAMA. 1943;123(3):125-131. doi:10.1001/jama.1943.02840380001001

Investigations have continued in a search for more therapeutically effective sulfonamides which at the same time provoke less toxic manifestations. In our experience at the University of Minnesota Hospitals, sulfadiazine has proved to be less toxic than sulfathiazole, sulfapyridine and sulfanilamide. Nevertheless it has been found that renal complications are not uncommonly associated with sulfadiazine therapy. For this reason the therapeutic possibilities of the monomethyl derivative of sulfadiazine were investigated. This report presents the results that have been obtained in the treatment of 116 patients with sulfamerazine and its sodium salt.

Sulfamerazine, the monomethyl derivative of sulfadiazine, is 2-sulfanilamido-4-methylpyrimidine. The dimethyl derivative of sulfadiazine is known as sulfamethazine and is 2-sulfanilamido-4,6 dimethyl-pyrimidine. Sulfamerazine was first described by Robin and his associates.1 They found that sulfamerazine was two and one half times as soluble in water as sulfadiazine. Its acetylated form had almost the same solubility as free sulfamerazine in